Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xiangxue Pharma Approved for China Trials of Brain Cancer Drug

publication date: May 25, 2017
Guangzhou Xiangxue Pharma received an IND approval from the CFDA to begin clinical trials of a novel treatment for glioblastoma. The candidate, KX-02, is a Src protein tyrosine kinase inhibitor that Xiangxue in-licensed from Athenex Pharma of New York State in 2012. KX-02 was granted the IND approval less than a year after filing (the wait time will be lowered to two months under new rules) as a Class 1 New Drug in China. Athenex received approval to begin US clinical trials for the drug in 2014. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here